Search

Your search keyword '"Yao, J.C."' showing total 75 results

Search Constraints

Start Over You searched for: Author "Yao, J.C." Remove constraint Author: "Yao, J.C." Database Unpaywall Remove constraint Database: Unpaywall
75 results on '"Yao, J.C."'

Search Results

1. 46MO FRESCO-2: A global / multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer

2. LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer

3. Analyse finale de la survie globale dans l’étude de phase 3 NETTER-1 du Lu-DOTATATE chez les patients atteints de tumeurs neuroendocrines de l’intestin moyen

4. 1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses

8. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

9. Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

11. Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study

12. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

20. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

21. 177 Lu-Dotatate améliore significativement la survie sans progression des patients atteints de tumeurs neuroendocrines métastatiques progressives de l’intestin moyen : résultats de l’essai de phase III NETTER-1

27. Everolimus (Eve) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (Pnet): Final Overall Survival (Os) Results of a Randomized, Double-Blind, Placebo (Pbo)-Controlled, Multicenter Phase III Trial (Radiant-3)

29. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer

34. 6561 POSTER Updated Survival and Safety Data From RADIANT-3 – a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET)

Catalog

Books, media, physical & digital resources